Thailand Hub of Talents in Cancer Immunotherapy (TTCI Thailand)

Researchers from Chulalongkorn University have successfully established a novel human antibody heavy chain variable (VH)-only domain with potent activity against folate receptor alpha-positive solid tumor in CAR-T cell format. Second-generation FRalpha-targeted VH-based and scFv-based CAR-Ts show specifically target and kill ovarian cancer cells in dose- and time-dependent manners. Meaningfully, VH-based CAR-T cells elicited superior antitumor potency and persistence in tumor rechallenge experiment and displayed fewer exhausted T cells after 4 rounds of stimulation, as compared with their scFv-based counterparts.
This current research highlights the benefits of utilizing VH domain antibody in CAR-T immunotherapy, particularly in targeting tumor antigens, and explores development strategies for treating solid tumors.

Funding

This research was supported by the Second Century Fund (C2F), Chulalongkorn University.

Original Paper

Title of original paper: Efficiently targeting folate receptor alpha-positive ovarian cancer by human antibody VH domain-based chimeric antigen receptor (CAR)
Journal: JThe 29th Annual Meeting of Japanese Association of Cancer Immunology
DOI: https://jaci2025.com/en/index.html

Correspondence

Supannikar Tawinwung ([email protected])